{"ticker": {"uuid": "621fe7b6-7088-42ee-8897-c0a44458e7b3", "symbol": "AZN", "name": "AstraZeneca PLC", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "U.K. regulator reaffirms safety of childhood vaccination", "summary": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-12T13:13:40+00:00", "published_display": "12 Aug 2026 13:13", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.049111, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 69.9, "age_days": 1.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["HEALTHCARE", "Healthcare", "REGULATION", "Regulation", "SPLIT", "Split"], "evidence_basis": "", "score_included": true}, {"title": "How AstraZeneca\u2019s $400bn deal unravelled", "summary": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly \u00a34.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T04:00:28+00:00", "published_display": "12 Aug 2026 04:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Operating growth"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.10425, "evidence_share": 4.4, "evidence_share_display": "4.4", "freshness_pct": 72.1, "age_days": 1.4, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn\u2019t Buy This Merger Talk", "summary": "AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti", "url": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:34:45+00:00", "published_display": "11 Aug 2026 19:34", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Improving financial comparison", "Dilution risk", "Negative market reaction"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.105817, "evidence_share": 4.5, "evidence_share_display": "4.5", "freshness_pct": 83.9, "age_days": 1.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["M A", "M-A", "ONCOLOGY", "Oncology", "PATENT-EXPIRY", "PHARMA"], "evidence_basis": "", "score_included": true}, {"title": "Do Options Traders Know Something About AstraZeneca Stock We Don't?", "summary": "Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. Ho", "url": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "source_link": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:11:00+00:00", "published_display": "11 Aug 2026 14:11", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Improving financial comparison"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.055514, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 50.1, "age_days": 2.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "IMPLIED-VOLATILITY", "Implied Volatility", "OPTIONS-TRADING", "Options Trading"], "evidence_basis": "", "score_included": true}, {"title": "Hedge Funds are Bullish on AstraZeneca PLC (AZN)", "summary": "AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the W", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "source_link": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:04:27+00:00", "published_display": "11 Aug 2026 14:04", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Beat expectations", "Deteriorating financial comparison", "Contract or approval won", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.160972, "evidence_share": 6.8, "evidence_share_display": "6.8", "freshness_pct": 75.8, "age_days": 2.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share", "ONCOLOGY", "Oncology"], "evidence_basis": "", "score_included": true}, {"title": "MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?", "summary": "Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue", "url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:48:00+00:00", "published_display": "11 Aug 2026 13:48", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 79, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.209973, "evidence_share": 8.9, "evidence_share_display": "8.9", "freshness_pct": 75.7, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["ACQUISITIONS", "Acquisitions", "EARNINGS", "Earnings", "ONCOLOGY", "Oncology"], "evidence_basis": "", "score_included": true}, {"title": "Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves", "summary": "Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF [https://seekingalpha.com/symbol/RYKKF]), Mitsubishi UFJ Financial Group (MUFG [https://seekingalpha.com/symbol/MUFG]), Tokio Marine Holdings (TKOMF [https://seekingalpha.com/symbol/TKOMF]), AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), Nokia (NOK [https://seekingalpha.com/symbol/NOK]), Rent", "url": "https://seekingalpha.com/news/4630721-polen-international-equity-adds-nok-mufg-exits-aivaf-rnmbf-among-q2-moves?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4630721-polen-international-equity-adds-nok-mufg-exits-aivaf-rnmbf-among-q2-moves?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-11T13:36:48+00:00", "published_display": "11 Aug 2026 13:36", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Beat expectations", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.216058, "evidence_share": 9.1, "evidence_share_display": "9.1", "freshness_pct": 75.6, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["EARNINGS", "Earnings", "FINANCIALS", "Financials", "HEALTHCARE", "Healthcare"], "evidence_basis": "", "score_included": true}, {"title": "A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?", "summary": "Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m", "url": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:20:39+00:00", "published_display": "11 Aug 2026 13:20", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.130807, "evidence_share": 5.5, "evidence_share_display": "5.5", "freshness_pct": 81.8, "age_days": 2.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "EARNINGS", "Earnings", "FREE CASH FLOW", "Free Cash Flow"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals", "summary": "During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T05:43:32+00:00", "published_display": "11 Aug 2026 05:43", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Improving financial comparison"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176356, "evidence_share": 7.4, "evidence_share_display": "7.4", "freshness_pct": 79.3, "age_days": 2.3, "influence_label": "Low", "duplicate_count": 2, "topics": ["EARNINGS", "EARNINGS PER SHARE", "EARNINGS REPORT", "Earnings", "Earnings Per Share", "Earnings Report"], "evidence_basis": "", "score_included": true}, {"title": "Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?", "summary": "It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-hi", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T23:44:03+00:00", "published_display": "10 Aug 2026 23:44", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Beat expectations", "Strong Demand", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.179354, "evidence_share": 7.6, "evidence_share_display": "7.6", "freshness_pct": 69.8, "age_days": 2.6, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BALANCE SHEET", "Balance Sheet", "CLINICAL-TRIALS", "Clinical Trials", "DIVIDENDS", "Dividends"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY", "summary": "During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the\u2026 Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these\u2026 I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a", "url": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:07:30+00:00", "published_display": "10 Aug 2026 18:07", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.08992, "evidence_share": 3.8, "evidence_share_display": "3.8", "freshness_pct": 67.5, "age_days": 2.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["BALANCE SHEET", "BIOTECH", "Balance Sheet", "Biotech", "FDA-APPROVAL", "FOURTH QUARTER"], "evidence_basis": "", "score_included": true}, {"title": "Zimmer Biomet Q2 Earnings Call Highlights", "summary": "Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased 4.6%. Technology and hip products led performance: Hip sales grew 5.1%, while technology, data, bone cement and surgical sales surged 21.5%, supported by strong ROSA, TMINI and OrthoGrid adoption. Knee sales were nearly flat, with international weakness\u2014especially in China\u2014offsetting U.S. gains. Zimmer Biomet raised", "url": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "source_link": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-09T18:03:50+00:00", "published_display": "09 Aug 2026 18:03", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 74, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Deteriorating financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.141437, "evidence_share": 6.0, "evidence_share_display": "6", "freshness_pct": 58.8, "age_days": 3.8, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Free Cash Flow", "Growth Rate", "Guidance", "Healthcare"], "evidence_basis": "", "score_included": true}, {"title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "summary": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:05:04+00:00", "published_display": "09 Aug 2026 13:05", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 74, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Operating deterioration"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.151941, "evidence_share": 6.4, "evidence_share_display": "6.4", "freshness_pct": 57.1, "age_days": 4.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["CONSENSUS ESTIMATE", "Consensus Estimate", "EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share"], "evidence_basis": "", "score_included": true}, {"title": "SA Asks: What's the outlook for Big Pharma M&A?", "summary": "[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth", "url": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T19:28:35+00:00", "published_display": "08 Aug 2026 19:28", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 34, "tone_signals": ["Operating deterioration"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.104847, "evidence_share": 4.4, "evidence_share_display": "4.4", "freshness_pct": 62.3, "age_days": 4.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "FDA-APPROVAL", "Fda Approval", "M A", "M&A"], "evidence_basis": "", "score_included": true}, {"title": "Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets", "summary": "[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]), alongside weaker-than-expected U.S. payrolls data. U.S. nonfarm payrolls fell by 23,000 in July, missing economists' expectations for a", "url": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T17:12:36+00:00", "published_display": "08 Aug 2026 17:12", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Beat expectations", "Missed expectations", "Guidance raised", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.148382, "evidence_share": 6.3, "evidence_share_display": "6.3", "freshness_pct": 50.9, "age_days": 4.9, "influence_label": "Low", "duplicate_count": 2, "topics": ["AI", "CONSENSUS ESTIMATE", "Consensus Estimate", "EARNINGS", "EARNINGS PER SHARE", "EARNINGS REPORT"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven too", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T15:12:37+00:00", "published_display": "08 Aug 2026 15:12", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.114263, "evidence_share": 4.8, "evidence_share_display": "4.8", "freshness_pct": 61.2, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["CLINICAL-TRIALS", "Clinical Trials", "ONCOLOGY", "Oncology", "PARTNERSHIP", "PHARMA"], "evidence_basis": "", "score_included": true}, {"title": "Roche Stock Jumps as Morgan Stanley Sees Drug Breakout", "summary": "This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs ", "url": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:30:33+00:00", "published_display": "07 Aug 2026 19:30", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 70, "tone_signals": ["Analyst upgrade", "Positive market reaction"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.045272, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 26.3, "age_days": 5.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["EARNINGS ESTIMATE", "Earnings Estimate", "FDA-APPROVAL", "Fda Approval", "INTRINSIC VALUE", "Intrinsic Value"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca, Jaguar Land Rover Gain Access to UK's Fast-Track Visa", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%2C+Jaguar+Land+Rover+Gain+Access+to+UK%27s+Fast-Track+Visa%22+%22MT+Newswires%22", "source_link_is_lookup": true, "source_name": "MT Newswires", "published_at": "2026-08-06T02:17:31.795934+00:00", "published_display": "06 Aug 2026 02:17", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00553, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 7.5, "age_days": 7.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Stock+Plunges+7.7%25+on+Reported+%24400+Billion+Merger+Talks%22+%22GuruFocus.com%22", "source_link_is_lookup": true, "source_name": "GuruFocus.com", "published_at": "2026-08-03T21:07:27.644620+00:00", "published_display": "03 Aug 2026 21:07", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Negative market reaction"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.0505, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 38.2, "age_days": 9.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%2C+Bristol+Myers+held+merger+talks%2C+Financial+Times+reports+%28AZN%3ANYSE%29%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-08-02T20:09:47.122456+00:00", "published_display": "02 Aug 2026 20:09", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029808, "evidence_share": 1.3, "evidence_share_display": "1.3", "freshness_pct": 34.5, "age_days": 10.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+and+Daiichi+win+EU+label+expansion+for+Datroway+in+breast+cancer%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-08-02T13:28:53.480070+00:00", "published_display": "02 Aug 2026 13:28", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001367, "evidence_share": 0.1, "evidence_share_display": "<0.1", "freshness_pct": 2.2, "age_days": 11.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Xencor+rises+as+AstraZeneca+royalty+row+ends+%28XNCR%3ANASDAQ%29%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-07-31T03:50:21.662589+00:00", "published_display": "31 Jul 2026 03:50", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000595, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 1.0, "age_days": 13.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Analyst Report: AstraZeneca PLC", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Analyst+Report%3A+AstraZeneca+PLC%22+%22Argus+Research%22", "source_link_is_lookup": true, "source_name": "Argus Research", "published_at": "2026-07-30T03:30:20.889204+00:00", "published_display": "30 Jul 2026 03:30", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002341, "evidence_share": 0.1, "evidence_share_display": "<0.1", "freshness_pct": 3.6, "age_days": 14.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca PLC (AZN) Stock Forecasts", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+PLC+%28AZN%29+Stock+Forecasts%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-07-28T07:47:48.541003+00:00", "published_display": "28 Jul 2026 07:47", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000175, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.4, "age_days": 16.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%27s+%242.63+Earnings+Beat+Supports+%2480+Billion+Revenue+Target%22+%22GuruFocus.com%22", "source_link_is_lookup": true, "source_name": "GuruFocus.com", "published_at": "2026-07-27T21:00:25.864473+00:00", "published_display": "27 Jul 2026 21:00", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 75, "tone_signals": ["Beat expectations"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.021078, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 9.9, "age_days": 16.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca stock trades steadily as oncology and cardiovascular growth underpin recent earnings", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+stock+trades+steadily+as+oncology+and+cardiovascular+growth+underpin+recent+earnings%22+%22Ad-hoc-news.de%22", "source_link_is_lookup": true, "source_name": "Ad-hoc-news.de", "published_at": "2026-07-27T14:22:41.436539+00:00", "published_display": "27 Jul 2026 14:22", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007808, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 9.5, "age_days": 17.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%27s+%28AZN%29+Etcamah+Secures+EU+Approval+for+Breast+Cance%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-23T13:36:31.210350+00:00", "published_display": "23 Jul 2026 13:36", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Contract or approval won"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.025278, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 12.5, "age_days": 21.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Wins+EU+Approval+for+Breast-Cancer+Drug+as+U.S.+Review+Continues%22+%22The+Wall+Street+Journal%22", "source_link_is_lookup": true, "source_name": "The Wall Street Journal", "published_at": "2026-07-23T10:30:22.262872+00:00", "published_display": "23 Jul 2026 10:30", "source_kind": "editorial_wire", "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Contract or approval won"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.041595, "evidence_share": 1.8, "evidence_share_display": "1.8", "freshness_pct": 12.3, "age_days": 21.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28AZN%29+Faces+Changes+Amid+New+U.S.+Drug+Tariff+Regula%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-22T02:30:19.544242+00:00", "published_display": "22 Jul 2026 02:30", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2.2e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 22.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Tokenized+Stock+price+today%2C+AZNX+to+USD+chart%2C+marketcap+and+volume%22+%22CryptoSlate%22", "source_link_is_lookup": true, "source_name": "CryptoSlate", "published_at": "2026-07-17T10:14:39.135553+00:00", "published_display": "17 Jul 2026 10:14", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 27.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (LSE:AZN) Stock Could Trade At A 46% Discount After Wainua Setback", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28LSE%3AAZN%29+Stock+Could+Trade+At+A+46%25+Discount+After+Wainua+Setback%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-07-15T11:11:10.557665+00:00", "published_display": "15 Jul 2026 11:11", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 29.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca pays up to $1.5bn to license Dizal Pharma\u2019s lung cancer drug", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+pays+up+to+%241.5bn+to+license+Dizal+Pharma%E2%80%99s+lung+cancer+drug%22+%22Pharmaceutical+Technology%22", "source_link_is_lookup": true, "source_name": "Pharmaceutical Technology", "published_at": "2026-07-15T04:40:22.430206+00:00", "published_display": "15 Jul 2026 04:40", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 29.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "by_tier": {"direct": [{"title": "U.K. regulator reaffirms safety of childhood vaccination", "summary": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-12T13:13:40+00:00", "published_display": "12 Aug 2026 13:13", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "46b3f23a3cbbf72aa4fa4eff600d629dac6ffd5d600b532526e1abeb25fd4333", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.496, "provider_directional_mass": 0.1449, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.049111, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 69.9, "age_days": 1.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["HEALTHCARE", "Healthcare", "REGULATION", "Regulation", "SPLIT", "Split"], "evidence_basis": "", "score_included": true}, {"title": "How AstraZeneca\u2019s $400bn deal unravelled", "summary": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly \u00a34.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T04:00:28+00:00", "published_display": "12 Aug 2026 04:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "dca284bb066b60bbf91f93101142188fab3d49b0b2476f9732ab4e090f4f98c0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.611, "provider_directional_mass": 0.089, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Operating growth"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.10425, "evidence_share": 4.4, "evidence_share_display": "4.4", "freshness_pct": 72.1, "age_days": 1.4, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn\u2019t Buy This Merger Talk", "summary": "AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti", "url": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:34:45+00:00", "published_display": "11 Aug 2026 19:34", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "d5f6b937de223e09167f8ed5a604f4407deb20166ac658448dc0e69114a6b5ef", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.701, "provider_directional_mass": 0.117, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.733, "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Improving financial comparison", "Dilution risk", "Negative market reaction"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.105817, "evidence_share": 4.5, "evidence_share_display": "4.5", "freshness_pct": 83.9, "age_days": 1.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["M A", "M-A", "ONCOLOGY", "Oncology", "PATENT-EXPIRY", "PHARMA"], "evidence_basis": "", "score_included": true}, {"title": "Do Options Traders Know Something About AstraZeneca Stock We Don't?", "summary": "Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. Ho", "url": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "source_link": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:11:00+00:00", "published_display": "11 Aug 2026 14:11", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "b51a9c0acb44843e99204d8fb453958beffc103c488dbbba819b3ed9a4d2d207", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.576, "provider_directional_mass": 0.1, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Improving financial comparison"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.055514, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 50.1, "age_days": 2.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "IMPLIED-VOLATILITY", "Implied Volatility", "OPTIONS-TRADING", "Options Trading"], "evidence_basis": "", "score_included": true}, {"title": "Hedge Funds are Bullish on AstraZeneca PLC (AZN)", "summary": "AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the W", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "source_link": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:04:27+00:00", "published_display": "11 Aug 2026 14:04", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "157f29885eab9b04cf8a5a81af1300536ff187ac011a500c0ee253bb620d6e35", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.746, "provider_directional_mass": 0.2062, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.516, "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Beat expectations", "Deteriorating financial comparison", "Contract or approval won", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.160972, "evidence_share": 6.8, "evidence_share_display": "6.8", "freshness_pct": 75.8, "age_days": 2.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share", "ONCOLOGY", "Oncology"], "evidence_basis": "", "score_included": true}, {"title": "MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?", "summary": "Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue", "url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:48:00+00:00", "published_display": "11 Aug 2026 13:48", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "8dc753318c40bcc1666bbc6fb48d58022a30d0148989be9442b7bb88150302e2", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.787, "provider_directional_mass": 0.227, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.23, "sentiment": "positive", "sentiment_pct": 79, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.209973, "evidence_share": 8.9, "evidence_share_display": "8.9", "freshness_pct": 75.7, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["ACQUISITIONS", "Acquisitions", "EARNINGS", "Earnings", "ONCOLOGY", "Oncology"], "evidence_basis": "", "score_included": true}, {"title": "Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves", "summary": "Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF [https://seekingalpha.com/symbol/RYKKF]), Mitsubishi UFJ Financial Group (MUFG [https://seekingalpha.com/symbol/MUFG]), Tokio Marine Holdings (TKOMF [https://seekingalpha.com/symbol/TKOMF]), AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), Nokia (NOK [https://seekingalpha.com/symbol/NOK]), Rent", "url": "https://seekingalpha.com/news/4630721-polen-international-equity-adds-nok-mufg-exits-aivaf-rnmbf-among-q2-moves?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4630721-polen-international-equity-adds-nok-mufg-exits-aivaf-rnmbf-among-q2-moves?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-11T13:36:48+00:00", "published_display": "11 Aug 2026 13:36", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "5163a6f26c9a175deb8acba38edfd2997987adb8c3d49093fb12a769f084512d", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.709, "provider_directional_mass": 0.102, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Beat expectations", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.216058, "evidence_share": 9.1, "evidence_share_display": "9.1", "freshness_pct": 75.6, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["EARNINGS", "Earnings", "FINANCIALS", "Financials", "HEALTHCARE", "Healthcare"], "evidence_basis": "", "score_included": true}, {"title": "A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?", "summary": "Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m", "url": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:20:39+00:00", "published_display": "11 Aug 2026 13:20", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "03fdb7a288edfc21b40514616b180e7d9df53c218807c001e9d74b6a285253d5", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.612, "provider_directional_mass": 0.155, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.256, "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.130807, "evidence_share": 5.5, "evidence_share_display": "5.5", "freshness_pct": 81.8, "age_days": 2.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "EARNINGS", "Earnings", "FREE CASH FLOW", "Free Cash Flow"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals", "summary": "During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T05:43:32+00:00", "published_display": "11 Aug 2026 05:43", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "fe554c1191a7dbcaa26c115af12013eb71f4be342d20eec97d15a6594f5991b9", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.669, "provider_directional_mass": 0.156, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Improving financial comparison"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176356, "evidence_share": 7.4, "evidence_share_display": "7.4", "freshness_pct": 79.3, "age_days": 2.3, "influence_label": "Low", "duplicate_count": 2, "topics": ["EARNINGS", "EARNINGS PER SHARE", "EARNINGS REPORT", "Earnings", "Earnings Per Share", "Earnings Report"], "evidence_basis": "", "score_included": true}, {"title": "Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?", "summary": "It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-hi", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T23:44:03+00:00", "published_display": "10 Aug 2026 23:44", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "78c6a1bd2ad031fb0a3c1669ca0cca5e3c1df0cd3854841e10d7280098ea7d9b", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.766, "provider_directional_mass": 0.198, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.376, "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Beat expectations", "Strong Demand", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.179354, "evidence_share": 7.6, "evidence_share_display": "7.6", "freshness_pct": 69.8, "age_days": 2.6, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BALANCE SHEET", "Balance Sheet", "CLINICAL-TRIALS", "Clinical Trials", "DIVIDENDS", "Dividends"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY", "summary": "During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the\u2026 Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these\u2026 I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a", "url": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:07:30+00:00", "published_display": "10 Aug 2026 18:07", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "8b0ace502be00ea4bc72828a6487f37dc7a95891208f25bb0d9a938c27f240fa", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.614, "provider_directional_mass": 0.214, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.95, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.08992, "evidence_share": 3.8, "evidence_share_display": "3.8", "freshness_pct": 67.5, "age_days": 2.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["BALANCE SHEET", "BIOTECH", "Balance Sheet", "Biotech", "FDA-APPROVAL", "FOURTH QUARTER"], "evidence_basis": "", "score_included": true}, {"title": "Zimmer Biomet Q2 Earnings Call Highlights", "summary": "Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased 4.6%. Technology and hip products led performance: Hip sales grew 5.1%, while technology, data, bone cement and surgical sales surged 21.5%, supported by strong ROSA, TMINI and OrthoGrid adoption. Knee sales were nearly flat, with international weakness\u2014especially in China\u2014offsetting U.S. gains. Zimmer Biomet raised", "url": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "source_link": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-09T18:03:50+00:00", "published_display": "09 Aug 2026 18:03", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "74027870843f0593cb643644b9d6f9fd9fb11f95387d065058d48179815d88bd", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.742, "provider_directional_mass": 0.134, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.495, "sentiment": "positive", "sentiment_pct": 74, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Deteriorating financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.141437, "evidence_share": 6.0, "evidence_share_display": "6", "freshness_pct": 58.8, "age_days": 3.8, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Free Cash Flow", "Growth Rate", "Guidance", "Healthcare"], "evidence_basis": "", "score_included": true}, {"title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "summary": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:05:04+00:00", "published_display": "09 Aug 2026 13:05", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "d57b5b18af87a6c4c97d2c4c28d98cf6f03ef2e7928b939a0fe59ecb5ec288c0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.752, "provider_directional_mass": 0.154, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.445, "sentiment": "positive", "sentiment_pct": 74, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Operating deterioration"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.151941, "evidence_share": 6.4, "evidence_share_display": "6.4", "freshness_pct": 57.1, "age_days": 4.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["CONSENSUS ESTIMATE", "Consensus Estimate", "EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share"], "evidence_basis": "", "score_included": true}, {"title": "SA Asks: What's the outlook for Big Pharma M&A?", "summary": "[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth", "url": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T19:28:35+00:00", "published_display": "08 Aug 2026 19:28", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "fd6f6ddc120c4d3f8b5e3d484fa6bed2d394475902a0ec5eeeefda565db16bfa", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.614, "provider_directional_mass": 0.0989, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 34, "tone_signals": ["Operating deterioration"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.104847, "evidence_share": 4.4, "evidence_share_display": "4.4", "freshness_pct": 62.3, "age_days": 4.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "FDA-APPROVAL", "Fda Approval", "M A", "M&A"], "evidence_basis": "", "score_included": true}, {"title": "Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets", "summary": "[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]), alongside weaker-than-expected U.S. payrolls data. U.S. nonfarm payrolls fell by 23,000 in July, missing economists' expectations for a", "url": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T17:12:36+00:00", "published_display": "08 Aug 2026 17:12", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "3de5b53e39642d63ea3e66b9431f8d6721c947cda34a3c65a2fb2f0d754c1b1a", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.77, "provider_directional_mass": 0.132, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.284, "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Beat expectations", "Missed expectations", "Guidance raised", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.148382, "evidence_share": 6.3, "evidence_share_display": "6.3", "freshness_pct": 50.9, "age_days": 4.9, "influence_label": "Low", "duplicate_count": 2, "topics": ["AI", "CONSENSUS ESTIMATE", "Consensus Estimate", "EARNINGS", "EARNINGS PER SHARE", "EARNINGS REPORT"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven too", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T15:12:37+00:00", "published_display": "08 Aug 2026 15:12", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "2ce674b337483eaa8cdb7407eb2350e4630b953f63dafef1c2bbd3a4558cba28", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.614, "provider_directional_mass": 0.123, "relevance_score": 0.88388, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.114263, "evidence_share": 4.8, "evidence_share_display": "4.8", "freshness_pct": 61.2, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["CLINICAL-TRIALS", "Clinical Trials", "ONCOLOGY", "Oncology", "PARTNERSHIP", "PHARMA"], "evidence_basis": "", "score_included": true}, {"title": "Roche Stock Jumps as Morgan Stanley Sees Drug Breakout", "summary": "This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs ", "url": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:30:33+00:00", "published_display": "07 Aug 2026 19:30", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "21799ecf8ba147bbea3c70855c16c57934e4ad0655c700526e0bc6df6a621e81", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.712, "provider_directional_mass": 0.204, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.291, "sentiment": "positive", "sentiment_pct": 70, "tone_signals": ["Analyst upgrade", "Positive market reaction"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.045272, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 26.3, "age_days": 5.8, "influence_label": "Low", "duplicate_count": 2, "topics": ["EARNINGS ESTIMATE", "Earnings Estimate", "FDA-APPROVAL", "Fda Approval", "INTRINSIC VALUE", "Intrinsic Value"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca, Jaguar Land Rover Gain Access to UK's Fast-Track Visa", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%2C+Jaguar+Land+Rover+Gain+Access+to+UK%27s+Fast-Track+Visa%22+%22MT+Newswires%22", "source_link_is_lookup": true, "source_name": "MT Newswires", "published_at": "2026-08-06T02:17:31.795934+00:00", "published_display": "06 Aug 2026 02:17", "provider": "archive", "providers": ["archive"], "source_names": ["MT Newswires"], "source_kind": "publisher", "story_key": "94ebc99ab559f4bc115106813817d06a38fb910e9fa12a73d45ef9a3e1de7e79", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00553, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 7.5, "age_days": 7.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Stock+Plunges+7.7%25+on+Reported+%24400+Billion+Merger+Talks%22+%22GuruFocus.com%22", "source_link_is_lookup": true, "source_name": "GuruFocus.com", "published_at": "2026-08-03T21:07:27.644620+00:00", "published_display": "03 Aug 2026 21:07", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus.com"], "source_kind": "publisher", "story_key": "b1dac7841079fce894da64ca88b29ca41287644527a28dd9d813f0322f72509d", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.545, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Negative market reaction"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.0505, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 38.2, "age_days": 9.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%2C+Bristol+Myers+held+merger+talks%2C+Financial+Times+reports+%28AZN%3ANYSE%29%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-08-02T20:09:47.122456+00:00", "published_display": "02 Aug 2026 20:09", "provider": "archive", "providers": ["archive"], "source_names": ["Seeking Alpha"], "source_kind": "publisher", "story_key": "94de9addb3ec1a95cab020cf6b2ee9860d602c1af594603dcbc1f38ac7d72647", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029808, "evidence_share": 1.3, "evidence_share_display": "1.3", "freshness_pct": 34.5, "age_days": 10.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+and+Daiichi+win+EU+label+expansion+for+Datroway+in+breast+cancer%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-08-02T13:28:53.480070+00:00", "published_display": "02 Aug 2026 13:28", "provider": "archive", "providers": ["archive"], "source_names": ["Seeking Alpha"], "source_kind": "publisher", "story_key": "dedd7da8372e4ddc95b7ae7ee83aea826c2351528397aa68fbe7a7d90c07a91c", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001367, "evidence_share": 0.1, "evidence_share_display": "<0.1", "freshness_pct": 2.2, "age_days": 11.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Xencor+rises+as+AstraZeneca+royalty+row+ends+%28XNCR%3ANASDAQ%29%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-07-31T03:50:21.662589+00:00", "published_display": "31 Jul 2026 03:50", "provider": "archive", "providers": ["archive"], "source_names": ["Seeking Alpha"], "source_kind": "publisher", "story_key": "c89b97934a864b9460e5184b6d55257fbb1af99b85d846665651f51bb460bc02", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000595, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 1.0, "age_days": 13.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Analyst Report: AstraZeneca PLC", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Analyst+Report%3A+AstraZeneca+PLC%22+%22Argus+Research%22", "source_link_is_lookup": true, "source_name": "Argus Research", "published_at": "2026-07-30T03:30:20.889204+00:00", "published_display": "30 Jul 2026 03:30", "provider": "archive", "providers": ["archive"], "source_names": ["Argus Research"], "source_kind": "publisher", "story_key": "75677a0aabdef516c97cc6428538d90108766ddaf8761b5732ae81a74a7a2dac", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002341, "evidence_share": 0.1, "evidence_share_display": "<0.1", "freshness_pct": 3.6, "age_days": 14.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca PLC (AZN) Stock Forecasts", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+PLC+%28AZN%29+Stock+Forecasts%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-07-28T07:47:48.541003+00:00", "published_display": "28 Jul 2026 07:47", "provider": "archive", "providers": ["archive"], "source_names": ["Market source"], "source_kind": "aggregator", "story_key": "1ae7ab9075e4b0079d6dda5fb6a1ad72a3573fd9ee8a3f59fd4f7438f15e7563", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000175, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.4, "age_days": 16.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%27s+%242.63+Earnings+Beat+Supports+%2480+Billion+Revenue+Target%22+%22GuruFocus.com%22", "source_link_is_lookup": true, "source_name": "GuruFocus.com", "published_at": "2026-07-27T21:00:25.864473+00:00", "published_display": "27 Jul 2026 21:00", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus.com"], "source_kind": "publisher", "story_key": "f862896f71024bf9c4b01f195e04a0917a662eb64873328765a65683fe9c28db", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.59, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 75, "tone_signals": ["Beat expectations"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.021078, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 9.9, "age_days": 16.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca stock trades steadily as oncology and cardiovascular growth underpin recent earnings", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+stock+trades+steadily+as+oncology+and+cardiovascular+growth+underpin+recent+earnings%22+%22Ad-hoc-news.de%22", "source_link_is_lookup": true, "source_name": "Ad-hoc-news.de", "published_at": "2026-07-27T14:22:41.436539+00:00", "published_display": "27 Jul 2026 14:22", "provider": "archive", "providers": ["archive"], "source_names": ["Ad-hoc-news.de"], "source_kind": "publisher", "story_key": "b689702156efec609001b2d550017fa54d99d39f09b966233b53548a00c199f5", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007808, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 9.5, "age_days": 17.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%27s+%28AZN%29+Etcamah+Secures+EU+Approval+for+Breast+Cance%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-23T13:36:31.210350+00:00", "published_display": "23 Jul 2026 13:36", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus"], "source_kind": "publisher", "story_key": "4c6cddc865f18512eabb14944eea2b92420bbbba112fe913e73f90b58a08708f", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.564, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Contract or approval won"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.025278, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 12.5, "age_days": 21.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Wins+EU+Approval+for+Breast-Cancer+Drug+as+U.S.+Review+Continues%22+%22The+Wall+Street+Journal%22", "source_link_is_lookup": true, "source_name": "The Wall Street Journal", "published_at": "2026-07-23T10:30:22.262872+00:00", "published_display": "23 Jul 2026 10:30", "provider": "archive", "providers": ["archive"], "source_names": ["The Wall Street Journal"], "source_kind": "editorial_wire", "story_key": "30fef59f3f5f705e2b9b3f185b83a5d35457837ed95ae33b5cd30c9d70b3bd90", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.564, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Contract or approval won"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.041595, "evidence_share": 1.8, "evidence_share_display": "1.8", "freshness_pct": 12.3, "age_days": 21.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28AZN%29+Faces+Changes+Amid+New+U.S.+Drug+Tariff+Regula%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-22T02:30:19.544242+00:00", "published_display": "22 Jul 2026 02:30", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus"], "source_kind": "publisher", "story_key": "772f524b27737ecb8c133b331452753a4ab52ac7f11eeb5ce20284ad5161d60c", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2.2e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 22.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Tokenized+Stock+price+today%2C+AZNX+to+USD+chart%2C+marketcap+and+volume%22+%22CryptoSlate%22", "source_link_is_lookup": true, "source_name": "CryptoSlate", "published_at": "2026-07-17T10:14:39.135553+00:00", "published_display": "17 Jul 2026 10:14", "provider": "archive", "providers": ["archive"], "source_names": ["CryptoSlate"], "source_kind": "publisher", "story_key": "08825854e67612bfc825ec097050f77b128a7f59189582e6240eb41da5f8106e", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 27.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (LSE:AZN) Stock Could Trade At A 46% Discount After Wainua Setback", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28LSE%3AAZN%29+Stock+Could+Trade+At+A+46%25+Discount+After+Wainua+Setback%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-07-15T11:11:10.557665+00:00", "published_display": "15 Jul 2026 11:11", "provider": "archive", "providers": ["archive"], "source_names": ["Market source"], "source_kind": "aggregator", "story_key": "c1d180ce7a43ca1308e464dbd7507a84a96b3792aa1a49acd7b5f8d0e0fe2c05", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 29.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca pays up to $1.5bn to license Dizal Pharma\u2019s lung cancer drug", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+pays+up+to+%241.5bn+to+license+Dizal+Pharma%E2%80%99s+lung+cancer+drug%22+%22Pharmaceutical+Technology%22", "source_link_is_lookup": true, "source_name": "Pharmaceutical Technology", "published_at": "2026-07-15T04:40:22.430206+00:00", "published_display": "15 Jul 2026 04:40", "provider": "archive", "providers": ["archive"], "source_names": ["Pharmaceutical Technology"], "source_kind": "publisher", "story_key": "026ebd41c3a7ebde983474ed5b9dd25fb4c362cc7ffff77a45f27547a2016e7a", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 29.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "industry": [], "sector": []}, "total_fetched": 32, "total_unique": 32, "total_relevant": 32, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 17}, "raw_articles": 49, "unique_stories": 32, "duplicates_removed": 17, "relevant_stories": 32, "matched_archive_stories": 32, "current_evidence": 32, "direct_evidence": 32, "eodhd_articles": 17, "archive_articles": 15, "eodhd": {"configured": true, "status": "healthy", "calls_used": 365, "call_budget": 500, "budget_used_pct": 73.0, "requests_made": 73, "last_success_at": "2026-08-13T14:00:29.227446+00:00", "newest_seen_at": "2026-08-13T13:55:45+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 2981, "unmapped_mentions": 2063}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-10T08:02:15.039429+00:00", "durable_newest_article_at": "2026-08-09T18:03:50+00:00", "durable_story_count": 1}, "sentiment_summary": {"positive": 17, "negative": 2, "neutral": 13, "score": 64, "raw_score": 69, "total": 32, "evidence_count": 32, "effective_articles": 17.01, "information_mass": 2.37, "direct_story_count": 32, "direct_source_count": 12, "industry_story_count": 0, "sector_story_count": 0, "story_count": 32, "source_count": 12, "source_concentration": 0.4894, "direct_share": 100, "dispersion": 13, "confidence": 56, "evidence_status": "measured", "score_version": "evidence-v7", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-12T13:13:40+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 70, "events": [{"event": "earnings", "label": "Earnings", "weight": 5.75, "count": 10}, {"event": "general", "label": "Market update", "weight": 5.45, "count": 9}, {"event": "deals", "label": "Deals and strategy", "weight": 4.1, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 1.7, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.6, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.6, "count": 1}], "positive_events": 17, "negative_events": 2, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 17}, "raw_articles": 49, "unique_stories": 32, "duplicates_removed": 17, "relevant_stories": 32, "matched_archive_stories": 32, "current_evidence": 32, "direct_evidence": 32, "eodhd_articles": 17, "archive_articles": 15, "eodhd": {"configured": true, "status": "healthy", "calls_used": 365, "call_budget": 500, "budget_used_pct": 73.0, "requests_made": 73, "last_success_at": "2026-08-13T14:00:29.227446+00:00", "newest_seen_at": "2026-08-13T13:55:45+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 2981, "unmapped_mentions": 2063}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-10T08:02:15.039429+00:00", "durable_newest_article_at": "2026-08-09T18:03:50+00:00", "durable_story_count": 1}}, "market_context": {"has_market_context": true, "latest_close": 161.42, "latest_week": "2026-08-07", "one_week_move": -4.2, "four_week_move": -5.3, "twelve_week_move": -11.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.12536, "market_dynamics_buy_signal": false, "relative_strength": -19.357858, "fair_value_gap": 7.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.3488, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.2% over one week, -5.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 66, "badges": ["Sentiment-trend disagreement"], "opportunities": [], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 12}, {"label": "seekingalpha.com", "count": 5}, {"label": "Seeking Alpha", "count": 3}, {"label": "GuruFocus.com", "count": 2}, {"label": "Market source", "count": 2}, {"label": "GuruFocus", "count": 2}, {"label": "MT Newswires", "count": 1}, {"label": "Argus Research", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 32}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 10}, {"label": "Market update", "count": 9}, {"label": "Deals and strategy", "count": 7}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "64/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "56/100", "tone": "neutral", "text": "17.01 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "70/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "32", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "13/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.2% over one week, -5.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "U.K. regulator reaffirms safety of childhood vaccination"}], "updated_at": "2026-08-10T08:02:15.039429+00:00", "detail_intelligence": {"headline": "Constructive news tone", "summary": "The score uses 32 current company stories from 12 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 64, "display": "64", "tone": "positive", "note": "Constructive news tone"}, {"label": "Confidence", "value": 56, "display": "56", "tone": "neutral", "note": "building confidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "32 company stories"}, {"label": "Story agreement", "value": 87, "display": "87", "tone": "positive", "note": "13/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 47, "note": "2.37 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "12 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 58, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 87, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 51, "note": "less reliance on one publisher"}], "freshness": 58, "source_independence": 51, "timeline": [{"date": "2026-07-15", "label": "15 Jul", "count": 2, "score": 50, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-07-16", "label": "16 Jul", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-17", "label": "17 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-18", "label": "18 Jul", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-19", "label": "19 Jul", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-20", "label": "20 Jul", "count": 0, "score": null, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-21", "label": "21 Jul", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-22", "label": "22 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-23", "label": "23 Jul", "count": 2, "score": 67, "tone": "positive", "x": 294.7, "y": 104.1, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 2, "score": 68, "tone": "positive", "x": 421.0, "y": 102.2, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-07-28", "label": "28 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-31", "label": "31 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-03", "label": "03 Aug", "count": 1, "score": 40, "tone": "negative", "x": 642.1, "y": 153.2, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 1, "score": 57, "tone": "neutral", "x": 736.9, "y": 122.3, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-07", "label": "07 Aug", "count": 1, "score": 70, "tone": "positive", "x": 768.5, "y": 98.6, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-08", "label": "08 Aug", "count": 3, "score": 64, "tone": "positive", "x": 800.1, "y": 109.5, "volume_height": 22.3, "volume_y": 243.7}, {"date": "2026-08-09", "label": "09 Aug", "count": 2, "score": 74, "tone": "positive", "x": 831.7, "y": 91.3, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-10", "label": "10 Aug", "count": 2, "score": 69, "tone": "positive", "x": 863.2, "y": 100.4, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-11", "label": "11 Aug", "count": 7, "score": 73, "tone": "positive", "x": 894.8, "y": 93.1, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 2, "score": 62, "tone": "positive", "x": 926.4, "y": 113.2, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,135.0 105.2,135.0 263.1,135.0 294.7,104.1 421.0,102.2 452.6,135.0 515.8,135.0 547.4,135.0 610.6,135.0 642.1,153.2 736.9,122.3 768.5,98.6 800.1,109.5 831.7,91.3 863.2,100.4 894.8,93.1 926.4,113.2", "timeline_has_signal": true, "timeline_start": "15 Jul", "timeline_mid": "30 Jul", "timeline_end": "13 Aug", "momentum": {"label": "Stable", "tone": "neutral", "recent_score": 71, "prior_score": 68, "delta": 3, "recent_count": 11, "prior_count": 6, "volume_delta": 5, "reliable": true, "reliability_note": "Confirmed by at least two stories in both periods"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 11, "share": 34}, {"label": "4 to 7 days", "count": 6, "share": 19}, {"label": "8 to 14 days", "count": 5, "share": 16}, {"label": "15 to 21 days", "count": 4, "share": 12}, {"label": "22 to 30 days", "count": 6, "share": 19}], "source_profile": [{"label": "finance.yahoo.com", "count": 12, "share": 38, "score": 71, "tone": "positive"}, {"label": "seekingalpha.com", "count": 5, "share": 16, "score": 69, "tone": "positive"}, {"label": "Seeking Alpha", "count": 3, "share": 9, "score": 50, "tone": "neutral"}, {"label": "GuruFocus", "count": 2, "share": 6, "score": 67, "tone": "positive"}, {"label": "GuruFocus.com", "count": 2, "share": 6, "score": 50, "tone": "neutral"}, {"label": "Market source", "count": 2, "share": 6, "score": 50, "tone": "neutral"}, {"label": "The Wall Street Journal", "count": 1, "share": 3, "score": 67, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 10, "share": 31, "score": 75, "tone": "positive"}, {"label": "Market update", "count": 9, "share": 28, "score": 59, "tone": "positive"}, {"label": "Deals and strategy", "count": 7, "share": 22, "score": 61, "tone": "positive"}, {"label": "Analyst action", "count": 3, "share": 9, "score": 69, "tone": "positive"}, {"label": "Regulatory and legal", "count": 2, "share": 6, "score": 67, "tone": "positive"}, {"label": "Macro sensitivity", "count": 1, "share": 3, "score": 50, "tone": "neutral"}], "topics": [{"label": "Earnings", "count": 7, "share": 22}, {"label": "EARNINGS", "count": 7, "share": 22}, {"label": "Oncology", "count": 4, "share": 12}, {"label": "ONCOLOGY", "count": 4, "share": 12}, {"label": "Earnings Per Share", "count": 4, "share": 12}, {"label": "EARNINGS PER SHARE", "count": 4, "share": 12}, {"label": "Biotech", "count": 4, "share": 12}, {"label": "BIOTECH", "count": 4, "share": 12}, {"label": "Healthcare", "count": 3, "share": 9}, {"label": "FDA-APPROVAL", "count": 3, "share": 9}], "supporting": [{"label": "Direct evidence", "text": "32 current stories are mapped specifically to AZN."}, {"label": "Source breadth", "text": "The read spans 12 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 87/100."}], "tempering": [{"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "U.K. regulator reaffirms safety of childhood vaccination", "summary": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-12T13:13:40+00:00", "published_display": "12 Aug 2026 13:13", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.049111, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 69.9, "age_days": 1.0, "influence_label": "Low", "duplicate_count": 2, "topics": ["HEALTHCARE", "Healthcare", "REGULATION", "Regulation", "SPLIT", "Split"], "evidence_basis": "", "score_included": true}, "article_count": 32, "updated_at": "2026-08-10T08:02:15.039429+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 78.3, "label": "13 Feb 2026", "close": 201.34, "index": 100.0}, {"x": 78.4, "y": 69.2, "label": "20 Feb 2026", "close": 204.2, "index": 101.4}, {"x": 114.9, "y": 55.8, "label": "27 Feb 2026", "close": 208.45, "index": 103.5}, {"x": 151.3, "y": 100.7, "label": "06 Mar 2026", "close": 194.22, "index": 96.5}, {"x": 187.7, "y": 114.3, "label": "13 Mar 2026", "close": 189.9, "index": 94.3}, {"x": 224.2, "y": 134.2, "label": "20 Mar 2026", "close": 183.6, "index": 91.2}, {"x": 260.6, "y": 119.0, "label": "27 Mar 2026", "close": 188.42, "index": 93.6}, {"x": 297.0, "y": 71.5, "label": "03 Apr 2026", "close": 203.49, "index": 101.1}, {"x": 333.5, "y": 69.8, "label": "10 Apr 2026", "close": 204.03, "index": 101.3}, {"x": 369.9, "y": 67.3, "label": "17 Apr 2026", "close": 204.8, "index": 101.7}, {"x": 406.3, "y": 114.8, "label": "24 Apr 2026", "close": 189.75, "index": 94.2}, {"x": 442.8, "y": 130.6, "label": "01 May 2026", "close": 184.74, "index": 91.8}, {"x": 479.2, "y": 136.6, "label": "08 May 2026", "close": 182.85, "index": 90.8}, {"x": 515.6, "y": 140.6, "label": "15 May 2026", "close": 181.58, "index": 90.2}, {"x": 552.0, "y": 123.4, "label": "22 May 2026", "close": 187.03, "index": 92.9}, {"x": 588.5, "y": 127.7, "label": "29 May 2026", "close": 185.67, "index": 92.2}, {"x": 624.9, "y": 126.8, "label": "05 Jun 2026", "close": 185.95, "index": 92.4}, {"x": 661.3, "y": 149.5, "label": "12 Jun 2026", "close": 178.75, "index": 88.8}, {"x": 697.8, "y": 161.6, "label": "19 Jun 2026", "close": 174.93, "index": 86.9}, {"x": 734.2, "y": 119.0, "label": "26 Jun 2026", "close": 188.41, "index": 93.6}, {"x": 770.6, "y": 101.8, "label": "03 Jul 2026", "close": 193.87, "index": 96.3}, {"x": 807.1, "y": 175.6, "label": "10 Jul 2026", "close": 170.48, "index": 84.7}, {"x": 843.5, "y": 184.1, "label": "17 Jul 2026", "close": 167.79, "index": 83.3}, {"x": 879.9, "y": 183.0, "label": "24 Jul 2026", "close": 168.15, "index": 83.5}, {"x": 916.4, "y": 181.8, "label": "31 Jul 2026", "close": 168.52, "index": 83.7}, {"x": 952.8, "y": 204.2, "label": "07 Aug 2026", "close": 161.42, "index": 80.2}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 49, "confidence": 28, "stories": 9, "close": 188.41, "price_change": 7.7, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 24, "stories": 16, "close": 193.87, "price_change": 2.9, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 49, "confidence": 26, "stories": 24, "close": 170.48, "price_change": -12.1, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 44, "confidence": 27, "stories": 29, "close": 167.79, "price_change": -1.6, "x": 848.7, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 54, "tone": "neutral", "raw_score": 62, "confidence": 35, "stories": 27, "close": 168.15, "price_change": 0.2, "x": 885.1, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 54, "tone": "neutral", "raw_score": 61, "confidence": 31, "stories": 24, "close": 168.52, "price_change": 0.2, "x": 921.6, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 54, "tone": "neutral", "raw_score": 62, "confidence": 33, "stories": 23, "close": 161.42, "price_change": -4.2, "x": 958.0, "y": 122.6, "show_label": true, "label_y": 112.6}], "price_path": "42.0,78.3 78.4,69.2 114.9,55.8 151.3,100.7 187.7,114.3 224.2,134.2 260.6,119.0 297.0,71.5 333.5,69.8 369.9,67.3 406.3,114.8 442.8,130.6 479.2,136.6 515.6,140.6 552.0,123.4 588.5,127.7 624.9,126.8 661.3,149.5 697.8,161.6 734.2,119.0 770.6,101.8 807.1,175.6 843.5,184.1 879.9,183.0 916.4,181.8 952.8,204.2", "sentiment_path": "739.4,130.0 775.8,130.0 812.3,130.0 848.7,131.8 885.1,122.6 921.6,122.6 958.0,122.6", "score_version": "evidence-v7", "price_change": -19.8, "sentiment_change": 4, "recent_pairs": [{"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 54, "tone": "neutral", "raw_score": 62, "confidence": 33, "stories": 23, "close": 161.42, "price_change": -4.2, "x": 958.0, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 54, "tone": "neutral", "raw_score": 61, "confidence": 31, "stories": 24, "close": 168.52, "price_change": 0.2, "x": 921.6, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 54, "tone": "neutral", "raw_score": 62, "confidence": 35, "stories": 27, "close": 168.15, "price_change": 0.2, "x": 885.1, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 44, "confidence": 27, "stories": 29, "close": 167.79, "price_change": -1.6, "x": 848.7, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 49, "confidence": 26, "stories": 24, "close": 170.48, "price_change": -12.1, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 24, "stories": 16, "close": 193.87, "price_change": 2.9, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 49, "confidence": 28, "stories": 9, "close": 188.41, "price_change": 7.7, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 161.42, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug", "live_score_version": "evidence-v7", "comparable_to_live": true}, "sentiment_history": [{"label": "20 Jun 23:59", "short_label": "20 Jun", "collected_at": "2026-06-20T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 7, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "26 Jun 23:59", "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 9, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 11, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "01 Jul 23:59", "short_label": "01 Jul", "collected_at": "2026-07-01T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 15, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 16, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 17, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 18, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "06 Jul 23:59", "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 20, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Jul 23:59", "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 23, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 24, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Jul 23:59", "short_label": "12 Jul", "collected_at": "2026-07-12T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 25, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 26, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 28, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 29, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 6, "score_change_display": "+6", "confidence_change": 14, "article_change": 0, "tone": "neutral", "height": 10, "articles": 28, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": -5, "tone": "neutral", "height": 12, "articles": 23, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 10, "articles": 25, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 8, "articles": 25, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 8, "articles": 24, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 6, "articles": 25, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 25, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -3, "tone": "neutral", "height": 4, "articles": 22, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 2, "score_change_display": "+2", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 8, "articles": 23, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 3, "score_change_display": "+3", "confidence_change": 10, "article_change": 1, "tone": "neutral", "height": 14, "articles": 24, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": 5, "score_change_display": "+5", "confidence_change": 4, "article_change": 1, "tone": "positive", "height": 24, "articles": 25, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 2, "tone": "positive", "height": 26, "articles": 27, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 67, "delta": 17, "score_change": 4, "score_change_display": "+4", "confidence_change": 10, "article_change": 6, "tone": "positive", "height": 34, "articles": 33, "confidence": 59, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 2, "tone": "positive", "height": 32, "articles": 35, "confidence": 57, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "13 Aug 14:03", "short_label": "13 Aug", "collected_at": "2026-08-13T14:03:25.165684+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "positive", "height": 32, "articles": 34, "confidence": 55, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v7", "live_version": "evidence-v7", "comparable_to_live": true, "reconstructed": true, "observations": 37, "span_label": "54 days", "first_score": 48, "latest_score": 66, "net_change": 18, "net_change_display": "+18", "direction": "Strengthening", "high_score": 67, "low_score": 48, "latest_confidence": 55, "confidence_change": 26, "latest_articles": 34, "article_change": 33, "latest_label": "13 Aug 14:03", "latest_evidence_label": "Measured", "chart_rows": [{"label": "20 Jun 23:59", "short_label": "20 Jun", "collected_at": "2026-06-20T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 42.0, "y": 138.6}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 67.4, "y": 136.8}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 92.9, "y": 135.0}, {"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 118.3, "y": 135.0}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 7, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 143.8, "y": 135.0}, {"label": "26 Jun 23:59", "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 9, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 169.2, "y": 135.0}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 11, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 194.7, "y": 135.0}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 220.1, "y": 135.0}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 245.6, "y": 135.0}, {"label": "01 Jul 23:59", "short_label": "01 Jul", "collected_at": "2026-07-01T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 15, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 271.0, "y": 135.0}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 16, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 296.4, "y": 135.0}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 17, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 321.9, "y": 135.0}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 18, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 347.3, "y": 133.2}, {"label": "06 Jul 23:59", "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 20, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 372.8, "y": 133.2}, {"label": "07 Jul 23:59", "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 398.2, "y": 133.2}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 23, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 423.7, "y": 135.0}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 24, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 449.1, "y": 135.0}, {"label": "12 Jul 23:59", "short_label": "12 Jul", "collected_at": "2026-07-12T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 25, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 474.6, "y": 135.0}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 26, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 500.0, "y": 138.6}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 28, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 525.4, "y": 136.8}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 29, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 550.9, "y": 136.8}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 576.3, "y": 136.8}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 6, "score_change_display": "+6", "confidence_change": 14, "article_change": 0, "tone": "neutral", "height": 10, "articles": 28, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 601.8, "y": 125.9}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": -5, "tone": "neutral", "height": 12, "articles": 23, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 627.2, "y": 124.1}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 10, "articles": 25, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 652.7, "y": 125.9}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 8, "articles": 25, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 678.1, "y": 127.7}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 8, "articles": 24, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 703.6, "y": 127.7}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 6, "articles": 25, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 729.0, "y": 129.5}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 25, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 754.4, "y": 131.4}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -3, "tone": "neutral", "height": 4, "articles": 22, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 779.9, "y": 131.4}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 2, "score_change_display": "+2", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 8, "articles": 23, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 805.3, "y": 127.7}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 3, "score_change_display": "+3", "confidence_change": 10, "article_change": 1, "tone": "neutral", "height": 14, "articles": 24, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 830.8, "y": 122.3}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": 5, "score_change_display": "+5", "confidence_change": 4, "article_change": 1, "tone": "positive", "height": 24, "articles": 25, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 856.2, "y": 113.2}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 2, "tone": "positive", "height": 26, "articles": 27, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 881.7, "y": 111.3}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 67, "delta": 17, "score_change": 4, "score_change_display": "+4", "confidence_change": 10, "article_change": 6, "tone": "positive", "height": 34, "articles": 33, "confidence": 59, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 907.1, "y": 104.1}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 2, "tone": "positive", "height": 32, "articles": 35, "confidence": 57, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 932.6, "y": 105.9}, {"label": "13 Aug 14:03", "short_label": "13 Aug", "collected_at": "2026-08-13T14:03:25.165684+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "positive", "height": 32, "articles": 34, "confidence": 55, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 958.0, "y": 105.9}], "chart_points": "42.0,138.6 67.4,136.8 92.9,135.0 118.3,135.0 143.8,135.0 169.2,135.0 194.7,135.0 220.1,135.0 245.6,135.0 271.0,135.0 296.4,135.0 321.9,135.0 347.3,133.2 372.8,133.2 398.2,133.2 423.7,135.0 449.1,135.0 474.6,135.0 500.0,138.6 525.4,136.8 550.9,136.8 576.3,136.8 601.8,125.9 627.2,124.1 652.7,125.9 678.1,127.7 703.6,127.7 729.0,129.5 754.4,131.4 779.9,131.4 805.3,127.7 830.8,122.3 856.2,113.2 881.7,111.3 907.1,104.1 932.6,105.9 958.0,105.9", "changes": [{"label": "13 Aug 14:03", "short_label": "13 Aug", "collected_at": "2026-08-13T14:03:25.165684+00:00", "score": 66, "delta": 16, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "positive", "height": 32, "articles": 34, "confidence": 55, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 66, "delta": 16, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 2, "tone": "positive", "height": 32, "articles": 35, "confidence": 57, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 67, "delta": 17, "score_change": 4, "score_change_display": "+4", "confidence_change": 10, "article_change": 6, "tone": "positive", "height": 34, "articles": 33, "confidence": 59, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 2, "tone": "positive", "height": 26, "articles": 27, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": 5, "score_change_display": "+5", "confidence_change": 4, "article_change": 1, "tone": "positive", "height": 24, "articles": 25, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 3, "score_change_display": "+3", "confidence_change": 10, "article_change": 1, "tone": "neutral", "height": 14, "articles": 24, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 2, "score_change_display": "+2", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 8, "articles": 23, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -3, "tone": "neutral", "height": 4, "articles": 22, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}